Next 10 |
home / stock / jazz / jazz articles
President Joe Biden's administration is moving to reschedule cannabis from Schedule I to Schedule III under the Controlled Substances Act (CSA)...
Roy Bingham, CEO of BDSA, anticipates substantial growth in the U.S. cannabis market, projecting sales to reach nearly $46 billion by 2028. This gr...
On May 7, a recent SEC filing unveiled that Neena M Patil, EVP & Chief Legal Officer at Jazz Pharmaceuticals (NASDAQ:JAZZ) made an insider sell...
If there's love that could move the Earth, it's that of a parent towards a child. And, as the Chinese proverb says, ‘To understand your...
"Tell me and I forget, teach me and I may remember, involve me and I learn." Benjamin Franklin When it comes to the cannabis industry, one of the ...
Redx to receive $10 million upfront; potential for up to $870 million in development, regulatory and sales milestone payments in addition to royal...
An Australian, vertically integrated plant-based medicine company, Cannatrek, will collaborate with a Japanese University to empower research on m...
The negative sentiment observed in the stock market at the beginning of the year appears to persist, with index futures pointing to a lower opening...
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) announced top-line results from the Phase 2 trial of JZP150, an investigational small molecule selecti...
News, Short Squeeze, Breakout and More Instantly...
Jazz Pharmaceuticals plc Company Name:
JAZZ Stock Symbol:
NASDAQ Market:
President Joe Biden's administration is moving to reschedule cannabis from Schedule I to Schedule III under the Controlled Substances Act (CSA)...
Roy Bingham, CEO of BDSA, anticipates substantial growth in the U.S. cannabis market, projecting sales to reach nearly $46 billion by 2028. This gr...